US 8,282,922 B2Granted

Method of treating an auto-inflammatory syndrome with a human IL-1β binding antibody

AssigneeNovartis AG

InventorsHermann Gram, Thomas Jung

Life of this patent

Estimating the term…

Loading patent…

Abstract

This invention relates to a novel use of IL-1β-ligand/IL-1 receptor disrupting compounds (herein referred to as “IL-1beta Compounds”); such as small molecular compounds disrupting IL-1β ligand-IL-1 receptor interaction, IL-1β antibodies or IL-1 receptor antibodies, e.g. IL-1β binding molecules described herein, e.g. antibodies disclosed herein, e.g. IL-1β binding compounds or IL-1 receptor binding compounds, and/or RNA compounds decreasing either IL-1β ligands or IL-1 receptor protein levels, in the treatment and/or prevention of auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome and to methods of treating and/or preventing auto-inflammatory syndromes, e.g. Juvenile rheumatoid arthritis or adult rheumatoid arthritis syndrome, in mammals, particularly humans.

Claims9

Dependent claims

A method of treating an auto-inflammatory syndrome selected from the group consisting of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulin D syndrome (HIDS), Schnizler's syndrome, Behcet Disease, urticarial vasculitis and adult onset Still disease (AOSD) in a patient in need thereof, comprising administering to said patient an effective amount of a human IL-1beta binding antibody comprising an antigen binding site comprising:

a) at least one immunoglobulin heavy chain variable domain (VM) which comprises in sequence hypervariable regions CDR1, CDR2 and CDR3, said CDR1 comprising the amino acid sequence set forth as SEQ ID NO:3, said CDR2 comprising the amino acid sequence set forth as SEQ ID NO:4, and said CDR3 comprising the amino acid sequence set forth as SEQ ID NO:5;
and
b) at least one immunoglobulin heavy chain variable domain (VL) which comprises in sequence hypervariable regions CDR1′, CDR2′ and CDR3′, said CDR1′ comprising the amino acid sequence set forth as SEQ ID NO:6, said CDR2′ comprising the amino acid sequence set forth as SEQ ID NO:7, said CDR3′ comprising the ammo acid sequence set forth as SEQ ID NO:8,
wherein said antibody is parenterally administered at a dose between 0.1-50 mg of said antibody per kg body weight of the patient.

1 more element

Dependencies are inferred from the claim text.